| Name | Title | Contact Details |
|---|
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Arizona Organization of Nurse Executives is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Hyperice, our mission is to provide everyone with the most innovative technology in accelerating recovery time, preventing injury, and enhancing the body`s ability to move more efficiently. All Hyperice products are developed and tested to meet the standards of the world`s best athletes.
Chesapeake IRB and its Canadian affiliate, IRB Services, have been in business since 1993. They have established a reputation for excellence that is based on quality work, efficient processes, and excellent customer service. Chesapeake IRB`s schedule of 5 weekly meetings, daily expedited review capability, 4 day turnaround for protocols and 24-hour turnaround for Principal Investigators (PIs) has helped our clients become more competitive for industry sponsored studies; including Phase I research. While the majority of our studies are biomedical or device related, we have a broad range of social/behavioral studies that are often government or foundation funded. We work with you as a risk mitigation partner to meet your needs.
Health Medical Equipment Inc is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.